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ABSTRACT
Objective: The objective of this research was to develop a polyherbal formulation using four different herbs using obese diabetic rat’s model.
Methods: Rats received high-fat diet and alloxan was injected intraperitoneal to rats for induction of diabetes. In the preventive experiment, diabetic 
rats received Momordica charantia Linn. (200 and 400 mg/kg/day p.o), Eugenia jambolana Linn. (200 and 400 mg/kg/day p.o), Ziziphus mauritiana 
(200 and 400 mg/kg/day p.o), Acacia catechu (AC) (200 and 400 mg/kg/day p.o), and aqueous extract of all extracts (100 and 200 mg/kg/day p.o). 
Diabetic rats were also treated with glibenclamide (5 mg/kg p.o.) and orlistat (60 mg/kg/day p.o.) as reference standards.
Results: The results showed that the extract of M. charantia Linn., E. jambolana Linn., Z. mauritiana, and AC significantly (p<0.05) inhibited body 
weight gain, blood glucose, triglyceride, total cholesterol, low-density lipoprotein (LDL), very LDL, high-density lipoprotein cholesterol, serum 
glutamic pyruvic transaminase, serum glutamic oxaloacetic transaminase, and fasting blood glucose in a dose-dependent manner. Extracts treated 
rats at doses of 200 and 400 mg/kg improved dyslipidemia in high-fat diet (HFD)-induced obese rats by enhancing their lipid metabolism when 
compared to the HFD control.
Conclusion: The results obtained in this research work clearly showed that taken together the extract of M. charantia Linn., E. jambolana Linn., 
Z. mauritiana Lam. AC Willd., and aqueous extract of all extracts has potential as a preventive agent for type 2 diabetes mellitus (and possibly obesity) 
and deserves clinical trial in the near future.
Keywords: Momordica charantia Linn., Eugenia jambolana Linn., Ziziphus mauritiana, Acacia catechu, Antidiabetic, Antiobesity.
INTRODUCTION
Diabetes and obesity are chief health crisis and mainly age-related 
metabolic disorders. Diabetes is the main cause of morbidity and 
mortality worldwide. Obesity is linked with the progression of diabetes 
mellitus. High levels of glycerol, fatty acids, enzymes, pro-inflammatory 
markers, and other obese entities build up insulin resistance in obese 
persons [1]. Increased intake of high caloric (energy and fat) food 
promotes body fat storage and greater body weight and adiposity in 
humans and animals. Over-the-counter remedies based on nutritional 
supplements are extremely popular, especially with respect to obesity 
and body composition. Inhibition of the digestion and absorption of 
dietary fat has been used as targets in obesity treatment.
The prevalence of obesity is rising dramatically among all ages with 
the changes of lifestyles and dietary fat intake [2]. Obesity represents a 
serious health problem that increased the risk for many diseases such as 
cardiovascular diseases, hypertension, and diabetes mellitus [3]. Obesity 
and insulin resistance are strongly associated with the infiltration of 
adipose tissue by inflammatory cells [4]. Diabetes mellitus is a chronic 
and progressive metabolic disease characterized by hyperglycemia 
due to insulin deficiency, or insulin resistance, or both. Hyperglycemia 
occurs when the cells become unable to utilize glucose and/or the liver 
and skeletal muscles cannot store glycogen [5,6]. Drugs such as insulin 
or oral hypoglycemic agents such as biguanides or sulfonylurea as 
are used primarily to control symptoms by decreasing concentration 
of glucose in blood. Secondary aim of such medications is to prevent 
long-term diabetic complications as described eatrlier by eliminating 
various risk factors [7]. Insulin resistance, a common accompaniment 
of obesity, is a major risk factor for diabetes mellitus [8]. Because 
synthetic chemical drugs prescribed for treating obesity and diabetes 
had many adverse side effects; therefore, there is a great need to search 
for complementary alternative medicine, particularly from medicinal 
plants. India has a rich history of using various potent herbs and herbal 
components for treating diabetes. Medicinal plant or herb has a variety 
of metabolites, aliphatic and aromatic compounds have the basic 
skeleton of organic molecules, which have various functional groups 
that make their ability to alter the various metabolic pathways make 
them medicinally important.
Herbal drugs are prescribed widely because of their effectiveness, 
less side effects, and relatively low cost [9]. Momordica charantia 
Linn., a valuable plant, belongs to the Cucurbitaceae family; it is 
commonly known as bitter gourd, balsam pear, bitter melon, kugua, 
or karela [10]. The generic name “Momordica” comes from Latin, 
meaning “to bite,” which refers to its leaf with serrated edges which 
looks as if it has been bitten [11]. Eugenia jambolana Linn. is the 
member of Myrtaceae family. It is also known in Hindi as jamun, 
jambo, jambul, jamhool, in English as black plum, purple plum, 
and black berry, and nerudu in Telugu [12]. Ziziphus mauritiana, a 
member from the family Rhamnaceae with local name Ber, is a fruit 
tree, which grows in tropical and subtropical regions of the world. 
It is called as jujube tree or Indian jujube [13]. Acacia catechu (L.f.) 
Willd. or Khair (AC), belonging to the family Mimosaceae, is used in 
most of the herbal preparations of Ayurveda in India [14,15]. In view 
of the above facts, the present study was undertaken to determine the 
antidiabetic and antiobesity effect of M. charantia Linn., E. jambolana 
Linn., Z. mauritiana, and AC and combination consisting of aqueous 
extract of all extracts. The effects on diet-induced changes in body 
weight, plasma glucose, triglyceride (TG), cholesterol and low-
density lipoprotein in high-fat diet (HFD), and alloxan-induced rats 
were evaluated to study the same.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i8.27789
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MATERIALS AND METHODS
Authentication of plants
Identification of plant was done by Dr. C.K. Nigwal (Department of 
Botany), P.G. College of Mandsaur (Madhya Pradesh).
Plant materials
Fresh plant material of M. charantia Linn., E. jambolana Linn., 
Z. mauritiana, and AC was collected from the local market. Air-dried 
plant materials were crushed to coarse powder, aqueous extract of 
M. charantia Linn., E. jambolana Linn., and Z. mauritiana was obtained, 
and AC was extracted exhaustively in a Soxhlet with ethanol. The extract 
was concentrated under reduced pressure to yield viscous mass. The 
aqueous and ethanolic extract was kept in airtight containers in a deep 
freeze maintained at 4°C until the time of further use.
Chemicals
Normal saline and other graded chemicals: Drug solutions were 
prepared fresh and doses are expressed in terms of their free bases. 
Glibenclamide was used as standard drugs for comparison with various 
extracts. Alloxan monohydrate (Sigma-Aldrich, USA), lipid profile 
estimation kit (Transasia Bio-Medical Limited, Mumbai, India), and 
other chemicals and solvent obtained from Qualigens, India, were used.
Instruments
Weighing of animals was done by digital balance, Shimadzu, and blood 
was collected by hematocrit capillary, Spectrum, India.
Animals
Wistar rats (150–200 g) were group housed (n=6) under a standard 
12 h light/dark cycle and controlled conditions of temperature and 
humidity (25±2°C, 55–65%). Rats received standard rodent chow and 
water ad libitum. Rats were acclimatized to laboratory conditions for 
7 days before carrying out the experiments. All the experiments were 
carried in a noise-free room between 08.00 and 15.00 h. Separate 
group (n=6) of rats was used for each set of experiments. The animal 
studies were approved by the Institutional Animal Ethics Committee, 
constituted for the purpose of control and supervision of experimental 
animals by Ministry of Environment and Forests, Government of India, 
New Delhi, India.
Toxicity study
For the acute oral toxicity and lethal dose 50 (LD50) determination, 
the organization for economic cooperation and development (OECD) 
guideline 423 was followed. As per OECD guidelines, a step-wise 
procedure with the use of three animals of a single sex per step was 
followed. Absence or presence of compound-related mortality of the 
animal doses at one step will determine the next step, i.e., no further 
testing needed, dosing of three additional animals with the same dose, 
and dosing of three additional animals at the next higher or the next 
lower dose levels.
Experimental model
After 28 days of administration of HFD and on day 29, alloxan was 
injected intraperitoneal to rats. After 3 days, rats were kept on 
overnight fasting in polypropylene cages with fasting bottom grills 
and water ad libitum. After 72 h of alloxination, blood glucose level 
was checked. Approximately 200 μl blood was collected from each 
animal by retro-orbital sinus in 0.5 ml Eppendorf tubes (Tarsons 
Products Pvt. Ltd., Kolkata, India) containing 20 μl of 20% sodium 
fluoride solution. Collected blood was centrifuged at 8000 rpm 
at temperature of 18–22°C for 10 min by centrifuge machine. 48 
animals were weighed, randomized, and divided into eight groups (6 
animals each) and were given following treatment for 14 days by oral 
route [16]:
• Group I - Normal (1% tween 80 solutions).
• Group II - Diabetic rats received only distilled water (negative 
control).
• Group III - Diabetic rats were treated with glibenclamide 
(5 mg/kg p.o.) with 1% tween 80 solutions.
• Group IV - Diabetic rats received orlistat (60 mg/kg/day p.o.) 
suspended in 1% tween 80 solutions.
• Group V - Diabetic rats received aqueous extract of M. charantiana 
Linn. (200 mg/kg/day p.o.) suspended in 1% tween 80 solutions.
• Group VI - Diabetic rats received aqueous extract of M. charantiana 
Linn. (400 mg/kg/day p.o.) suspended in 1% tween 80 solutions.
• Group VII - Diabetic rats received aqueous extract of E. jambolana 
Linn. (200 mg/kg/day p.o.) suspended in 1% tween 80 solutions.
• Group VIII - Diabetic rats received aqueous extract of E. jambolana 
Linn. (400 mg/kg/day p.o.) suspended in 1% tween 80 solutions.
• Group IX - Diabetic rats received aqueous extract of Z. maurantiana 
Lam. (200 mg/kg/day p.o.) suspended in 1% tween 80 solutions.
• Group X - Diabetic rats received aqueous extract of Z. maurantiana 
Lam. (400 mg/kg/day p.o.) suspended in 1% tween 80 solutions.
• Group XI - Diabetic rats received ethanolic extract of AC Willd. 
(200 mg/kg/day p.o.) suspended in 1% tween 80 solutions.
• Group XII - Diabetic rats received ethanolic extract of AC Willd. 
(400 mg/kg/day p.o.) suspended in 1% tween 80 solutions.
• Group XII - Diabetic rats received aqueous extract of all extracts 
(100 mg each extract/kg/day p.o.) suspended in 1% tween 80 
solutions.
• Group XIV - Diabetic rats received aqueous extract of all extracts 
(200 mg each extract/kg/day p.o.) suspended in 1% tween 80 
solutions.
Blood sampling and plasma assay
For blood glucose determination, blood was withdrawn by tail snipping 
technique. For various lipid profile and biochemical parameters 
estimation, blood was collected from ophthalmic venous plexus 
by retro-orbital bleeding technique [17]. The blood samples were 
placed on ice, centrifuged, and the plasma was stored at −20°C until 
assayed. The blood glucose concentration was determined using the 
glucose oxidase method [18]. TG, total cholesterol (TC), TG, TC, low-
density lipoprotein (LDL), very LDL (VLDL), high-density lipoprotein 
(HDL) cholesterol, and fasting blood glucose were determined using 
commercially available kits. Serum glutamic pyruvic transaminase 
(SGPT) and serum glutamic oxaloacetic transaminase (SGOT) were 
determined using the method of Reitman and Frankel [19].
Statistical analysis
Variables of interest were entered and all data analyzed using 
GraphPad Instant 3.06 software version 14 for Windows XP (Microsoft 
Corporation). All statistical analyses are expressed as mean ± standard 
error of the mean (SEM). Data were analyzed by one-way ANOVA, where 
applicable p<0.05 was considered statistically significant, compared 
with vehicle followed by Dunnett’s test.
RESULTS AND DISCUSSION
The acute oral toxicity studies and selection of doses were carried out as 
per guidelines of OECD, draft guidelines 423 received from Committee 
for the Purpose of Control and Supervision of Experiments on Animals, 
Ministry of Social Justice and Empowerment, Government of India. 
Healthy Wistar rats of either sex weighing between 150 and 200 g were 
used for acute toxicity study to determine LD50 of extract/fractions. 
The animals were randomly selected, marked to permit individual 
identification, and kept in their cages for 7 days before dosing to allow 
for acclimatization to the laboratory condition. In acute toxicity study, 
no toxic symptoms were observed for polyherbal formulation (PHF) 
up to dose 2000 mg/kg body weight. All animals behaved normally. 
No neurological or behavioral effect could be noted. No mortality was 
found up to 14 days study. PHF was safe up to 2000 mg/kg.
Body weights (g) of the entire animal were measured at onset of study 
and end of study. Mean body weight change of all the groups is shown 
in Table 2.
Blood glucose (g) of the entire animals was measured at different times. 
Mean blood glucose changes of all the groups are shown in Table 2.
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Table 2: Antidiabetic activity of various extracts on blood glucose level in alloxan-induced diabetic rats for day 14
Group Drug Dose Blood glucose level (mg/dl)
0 h 1 h 2 h 3 h 4 h 5 h 6 h
I Normal 1% tween 
80
84.67±22.70 83.67±20.95 87.00±20.40 77.33±20.3 75.00±21.50 79.67±20.23 77.67±20.22
II Control 1% tween 
80
387.40±21.29 414.00±20.66 421.40±20.59 438.00±20.15 447.20±20.36 449.80±20.55 454.60±20.55
III Glibenclamide 5 mg/kg 
p.o.
362.80±20.86 310.40±20.12 271.60±21.62 250.80±20.57 230.60±20.55 190.50±22.53 175.5±4.46
IV Orlistat 60 mg/kg 
p.o.






























366.12±10.08 334.11±9.05 305.15±12.00 285.5±14.1 275.10±12.5 245.10±13.0 229.04±10.10
XI AC Willd. 200 mg/kg 
p.o.
364.20±20.27 340.14±12.15 309.20±17.10 297.4±14.6 280.10±11.5 259.20±12.0 237.00±12.09
XII AC Willd. 400 mg/kg 
p.o.
361.50±10.07 333.10±10.05 300.40±15.00 285.3±15.8 275.10±12.5 249.10±10.0 220.03±10.11
XIII PHF 100 mg/kg 
p.o.
364.10±15.17 315.12±10.09 290.40±15.00 279.3±11.6 255.10±12.5 217.60±20.01 195.60±21.03
XIV PHF 200 mg/kg 
p.o.
365.60±20.55 310.10±7.59 280.50±11.60 271.4±10.6 249.5±11.5 215.10±9.09 188.20±25.72
Values are expressed as mean±SEM. (n=6). Values are statistically significant at p<0.05 versus negative control group, respectively (one-way ANOVA followed by 
Dunnett’s test). Serum biochemistry was performed on day 14 using automatic serum biochemistry analyzer. PHF: Polyherbal formulation, SEM: Standard error of the 
mean
In this present study shows initial the animals treated with 
HFD - alloxan showed marked glucose intolerance which indicated 
that they developed diabetes. While on the 14th day, PHF showed its 
hypoglycemic activity compare to negative control with unexplained 
mechanism.
The increased in blood sugar is accompanied with the increase in TC, TG, 
LDL, VLDL, and fall of HDL. It is well known that in uncontrolled type 2 
diabetes mellitus, there will be an increase in TC, TG, LDL, VLDL, and TG 
with decrease in HDL, which contributes to the coronary artery disease. 
From this point of view, it is encouraging that the 14-day treatment of 
PHF and different extracts associated with reduced the elevated levels 
of TC, TG, LDL, and VLDL as compared to negative control in diabetic 
animals. There was increase in HDL also, which indicates that PHF may 
be beneficial to diabetic individuals with atherosclerosis since superior 
HDL level is associated with the lowered risk of the development of 
atherosclerosis in diabetes mellitus.
This antihyperglycemic effect of PHF on the alloxan diabetic rats 
suggests that its main mechanism may not be due to stimulating insulin 
release from pancreatic cells but may exert a direct action by promoting 
glucose utilization by peripheral tissues. We would need much more 
research work to study the mechanism.
The present study shown that biochemical parameters did not show any 
of the adverse effect of crude mixed extracts in rats. Liver enzymes such 
Table 1: Mean body weight change
Group Drug Dose Body weight (g)
Onset of study End of study
I Normal 1% tween 80 200.15±8.83 230.18±8.93
II Control 1% tween 80 230.20±15.62 195.30±8.37
III Glibenclamide 5 mg/kg p.o. 230.22±12.26 197.40±10.45
IV Orlistat 60 mg/kg p.o. 232.17±8.09 165.40±6.59
V Momordica charantia Linn. 200 mg/kg p.o. 230.54±6.63 219.17±10.85
VI Momordica charantia Linn. 400 mg/kg p.o. 225.50±6.63 209.17±5.85
VII Eugenia jambolana Linn. 200 mg/kg p.o. 235.80±8.23 220.10±10.37
VIII Eugenia jambolana Linn. 400 mg/kg p.o. 235.70±8.23 207.10±11.07
IX Ziziphus maurantiana Lam. 200 mg/kg p.o. 236.10±6.56 220.63±10.10
X Ziziphus maurantiana Lam. 400 mg/kg p.o. 235.18±7.66 205.93±11.10
XI AC Willd. 200 mg/kg p.o. 231.40±5.50 220.17±8.07
XII AC Willd. 400 mg/kg p.o. 236.50±7.50 210.47±9.07
XIII PHF 100 mg/kg p.o. 235.15±7.00 187.20±7.60
XIV PHF 200 mg/kg p.o. 230.10±8.00 175.10±6.59
Values are expressed as mean±SEM (n=6). Values are statistically significant at p<0.05 versus negative control group, respectively (one-way ANOVA followed by 
Dunnett’s test). PHF: Polyherbal formulation, SEM: Standard error of the mean, AC: Acacia catechu
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as SGOT and SGPT are considered to be biochemical markers for assessing 
liver function. The PHF significantly reduced the liver enzymes levels in 
experimental animal’s shows that combined therapy has hepatoprotective 
effect. During the experimentation, Wistar rats did not show any mortality 
or any other adverse effects when the rats fed orally with polyherbal 
extract at the doses of 100–200 mg/kg. Thus, the PHF has a good 
periphery of safety. However, when given in combination, i.e., diabetic + 
PHF hepatotoxicity was reduced and appeared comparable to negative 
control, serum biochemically as well as histologically. All diabetic-treated 
groups showed histopathological changes of varying degree of alveolar 
histiocytosis due to phospholipidosis. Histopathology data showed 
minimal hepatic degeneration and focal hepatocellular hypertrophy in 
negative control animals, which might be the effect of alloxan-induced 
free radical damage. Furthermore, these results indicated increased risk 
of hepatotoxicity in negative control animals than normal animals due 
to PHF and different extracts. Liver from diabetic + M. charantia Linn., 
E. jambolana Linn., Z. maurantiana Lam., and AC Willd. extract groups 
showed focal hepatocellular hypertrophy and degeneration indicating 
minimal hepatotoxicity due to increased peroxisome proliferation while 
diabetic + PHF group showed negligible potential of nephrotoxicity. The 
reduced histopathological changes in kidney from diabetic + PHF group 
indicated that combination improved nephrotoxicity in diabetic condition.
CONCLUSION
Obesity is associated with insulin resistance and cardiovascular disease 
risk factors. Therapeutic agents with both antidiabetic and antiobese 
Table 3: Effect of various extracts on TC and TG level in alloxan-induced diabetic rats after treatment
Group Drug Dose TC (mg/dl) TG (mg/dl)
I Normal 1% tween 80 78.6±2.05 99.16±13.07
II Control 1% tween 80 66.67±5.95 78.83±7.79
III Glibenclamide 5 mg/kg p.o. 57.83±2.45 56.50±6.00
IV Orlistat 60 mg/kg p.o. 53.66±3.06 49.5±5.48
V Momordica charantia Linn. 200 mg/kg p.o. 70.00±1.10 71.33±6.18
VI Momordica charantia Linn. 400 mg/kg p.o. 67.00±2.50 65.02±5.10
VII Eugenia jambolana Linn. 200 mg/kg p.o. 70.00±5.07 80.00±4.11
VIII Eugenia jambolana Linn. 400 mg/kg p.o. 64.01±5.00 76.01±4.60
IX Ziziphus maurantiana Lam. 200 mg/kg p.o. 72.00±8.08 69.99±2.05
X Ziziphus maurantiana Lam. 400 mg/kg p.o. 66.00±7.08 64.20±2.16
XI AC Willd. 200 mg/kg p.o. 67.00±3.10 70.00±5.16
XII AC Willd. 400 mg/kg p.o. 61.00±4.10 65.00±4.07
XIII PHF 100 mg/kg p.o. 59.00±2.45 62.00±2.10
XIV PHF 200 mg/kg p.o. 57.83±3.50 57.01±3.06
Values are expressed as mean±SEM. (n=6). Values are statistically significant at p<0.05 (one-way ANOVA followed by Dunnett’s test). PHF: Polyherbal formulation, 
SEM: Standard error of the mean, AC: Acacia catechu, TG: Triglyceride, TC: Total cholesterol
Table 4: Effect of various extracts on LDL and VLDL in alloxan-induced diabetic rats after treatment
Group Drug Dose LDL (mg/dl) VLDL (mg/dl)
I Normal 1% tween 80 17.8±3.60 19.83±2.07
II Control 1% tween 80 69.5±1.76 48.10±1.53
III Glibenclamide 5 mg/kg p.o. 53.4±5.16 42.30±0.54
IV Orlistat 60 mg/kg p.o. 46.4±2.71 37.10±0.60
V Momordica charantia Linn. 200 mg/kg p.o. 66.00±3.50 51.50±3.80
VI Momordica charantia Linn. 400 mg/kg p.o. 59.50±5.00 48.50±2.70
VII Eugenia jambolana Linn. 200 mg/kg p.o. 65.40±5.10 50.60±2.80
VIII Eugenia jambolana Linn. 400 mg/kg p.o. 60.00±4.50 47.55±1.70
IX Ziziphus maurantiana Lam. 200 mg/kg p.o. 66.00±5.10 51.00±1.80
X Ziziphus maurantiana Lam. 400 mg/kg p.o. 58.10±6.18 46.90±2.10
XI AC Willd. 200 mg/kg p.o. 65.00±2.10 50.00±2.70
XII AC Willd. 400 mg/kg p.o. 59.00±2.11 47.20±1.17
XIII PHF 100 mg/kg p.o. 49.6±5.06 44.8±0.17
XIV PHF 200 mg/kg p.o. 47.9±1.01 39.4±1.54
Values are expressed as mean±SEM. (n=6). Values are statistically significant at p<0.05 (one-way ANOVA followed by Dunnett’s test). LDL: Low-density lipoprotein, 
VLDL: Very low-density lipoprotein, SEM: Standard error of the mean, AC: Acacia catechu
Table 5: Effect of various extracts on HDL in alloxan-induced 
diabetic rats after treatment
Group Drug Dose HDL (mg/dl)
I Normal 1% tween 80 35.00±1.54
II Control 1% tween 80 32.50±1.70
III Glibenclamide 5 mg/kg p.o. 42.50±1.10
IV Orlistat 60 mg/kg p.o. 47.00±1.32
V Momordica 
charantia Linn.
200 mg/kg p.o. 39.40±1.15
VI Momordica 
charantia Linn.
400 mg/kg p.o. 40.30±1.50
VII Eugenia 
jambolana Linn.
200 mg/kg p.o. 38.50±4.14
VIII Eugenia 
jambolana Linn.
400 mg/kg p.o. 41.00±2.50
IX Ziziphus 
maurantiana Lam.
200 mg/kg p.o. 39.00±2.14
X Ziziphus 
maurantiana Lam.
400 mg/kg p.o. 41.00±1.80
XI AC Willd. 200 mg/kg p.o. 39.15±2.11
XII AC Willd. 400 mg/kg p.o. 40.20±2.38
XIII PHF 100 mg/kg p.o. 43.9±2.13
XIV PHF 200 mg/kg p.o. 45.8±4.38
Values are expressed as mean±SEM. (n=6). Values are statistically significant 
at p<0.05 (one-way ANOVA followed by Dunnett’s test). HDL: High-density 
lipoprotein, SEM: Standard error of the mean, AC: Acacia catechu
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effects are, therefore, particularly beneficial. Our results show that HFD 
rats treated with M. charantia Linn., E. jambolana Linn., Z. maurantiana 
Lam., AC Willd., and aqueous extract of all extracts underwent a time-
dependent reduction in body weight and cholesterol, TGs as well as 
controlling the glycemia reflecting antiobesity and antidiabetic activity. 
The plant material may exert their antidiabetic and antiobesity effects 
through actions that improve insulin sensitivity and the balance 
between food intake and energy expenditure.
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Table 6: Effect of various extracts on SGOT and SGPT in alloxan-induced diabetic rats after treatment
Group Drug Dose SGOT (IU/L) SGPT (IU/L)
I Normal 1% tween 80 29.32±1.53 22.27±1.85
II Control 1% tween 80 53.17±1.20 44.56±1.99
III Glibenclamide 5 mg/kg p.o. 41.35±0.95 41.27±1.50
IV Orlistat 60 mg/kg p.o. 34.01±1.10 29.89±1.98
V Momordica charantia Linn. 200 mg/kg p.o. 45.30±1.50 43.00±1.40
VI Momordica charantia Linn. 400 mg/kg p.o. 42.50±1.80 40.50±1.60
VII Eugenia jambolana Linn. 200 mg/kg p.o. 44.40±1.40 42.50±1.60
VIII Eugenia jambolana Linn. 400 mg/kg p.o. 41.80±1.78 39.50±1.70
IX Ziziphus maurantiana Lam. 200 mg/kg p.o. 45.00±1.50 42.00±1.50
X Ziziphus maurantiana Lam. 400 mg/kg p.o. 43.00±1.18 39.00±1.80
XI AC Willd. 200 mg/kg p.o. 45.04±1.52 41.80±1.50
XII AC Willd. 400 mg/kg p.o. 42.00±1.58 40.55±1.48
XIII PHF 100 mg/kg p.o. 40.34±1.62 38.86±1.33
XIV PHF 200 mg/kg p.o. 39.01±1.55 33.53±1.88
Values are expressed as mean±SEM (n=6). Values are statistically significant at p<0.05 (one-way ANOVA followed by Dunnett’s test). LDL: Low-density lipoprotein, 
VLDL: Very low-density lipoprotein, SEM: Standard error of the mean, AC: Acacia catechu, SGOT: Serum glutamic oxaloacetic transaminase, SGPT: Serum glutamic 
pyruvic transaminase
